| ORIGINAL ARTICLE |
|
| Year : 2013 | Volume
: 17
| Issue : 8 | Page : 584-587 |
|
|
Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Kolkata cohort of the A 1 chieve study
Anirban Majumder1, Awadhesh Kumar Singh2, Kalyan Kumar Gangopadhyay3, Ranjini Sen4, Raman Shetty4, Sujoy Majumdar5
1 KPC Medical College and Hospital, Kolkata, India
2 GD hospital and Diabetes Institute, Kolkata; Sun Valley Diabetes and Endocrine Centre, Guwahati, India
3 Fortis Hospital, Bangalore, India
4 Novo Nordisk India Pvt. Ltd., Bangalore, India
5 GD hospital and Diabetes Institute, Kolkata, India
Correspondence Address:
Raman Shetty
Novo Nordisk India Pvt. Ltd., Plot No. 32, 47 - 50, EPIP Area, Whitefield, Bangalore
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/2230-8210.122144
|
|
|
Background: The A 1 chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care across four continents. Materials and Methods: Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from Kolkata, India. Results: A total of 576 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Patients had started on or were switched to biphasic insulin aspart (n = 417), insulin detemir (n = 70), insulin aspart (n = 55), basal insulin plus insulin aspart (n = 19) and other insulin combinations (n = 15). At baseline, glycaemic control was poor for both insulin naïve (mean HbA 1 c: 8.3%) and insulin user (mean HbA 1 c: 8.6%) groups. After 24 weeks of treatment, both the groups showed improvement in HbA 1 c (insulin naïve: −1.3%, insulin users: −1.4%). SADRs including major hypoglycaemic events or episodes did not occur in any of the study patients. Conclusion: Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
Next article
